Skip Navigation

European Heart Journal 2004 25(5):431-436; doi:10.1016/j.ehj.2004.01.013
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (46)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mikhail, G. W
Right arrow Articles by Gatzoulis, M. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mikhail, G. W
Right arrow Articles by Gatzoulis, M. A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Clinical research

Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects

Ghada W Mikhaila, Sanjay K Prasada, Wei Lia, Paula Rogersa, Adrian H Chesterb, Stephanie Baynea, David Stephensc, Mohammed Khanb, J.S.R Gibbsd, Timothy W Evansa, Andrew Mitchella, Magdi H Yacoubb and Michael A Gatzoulisa,*

a Adult Congenital Heart Unit, Royal Brompton and Harefield NHS Trust, Sydney Street, London SW3 6NP UK
b National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, London, UK
c Imperial College of Science, Technology and Medicine, London, UK
d National Heart and Lung Institute, Imperial College of Science, Technology and Medicine and Hammersmith Hospitals NHS Trust, London, UK

* Corresponding author. Tel.: +44-207-351-8602; fax: +44-207-351-8629
E-mail address: m.gatzoulis{at}rbh.nthames.nhs.uk

Received 6 August 2003; revised 24 December 2003; accepted 22 January 2004

Abstract

Aim The treatment of patients with pulmonary arterial hypertension remains a challenge. We set out to investigate the use of sildenafil, a selective inhibitor of phosphodiesterase type 5, in patients with this disease.

Methods and results Ten patients (8 females, mean age 34.5±3.3 years) with pulmonary hypertension underwent right heart catheterisation with vasodilator testing using incremental doses of intravenous sildenafil without adverse events. All patients were subsequently commenced on oral sildenafil 50 mg t.d.s. Nine patients had repeat right heart catheterisation 3 months after the commencement of oral therapy. There was a significant reduction in mean pulmonary artery pressure (from 55.8±5.9 to 50.4±6.1 mmHg, ) and pulmonary vascular resistance (from 10.1±1.7 to 8.6±1.5 Wood units, ), and an increase in cardiac output (from 4.7±0.3 to 5.0±0.4 l/min, ). Furthermore, there was a significant increase in the 6-minute walk test, a mean of 112 m. In response to a quality-of-life questionnaire, patients indicated marked clinical improvement on sildenafil. Sildenafil was discontinued in 1 patient due to a transient visual disturbance. The only patient previously awaiting transplantation was removed from the active transplantation list.

Conclusions Sildenafil is well tolerated in its intravenous and oral forms and appears to improve both pulmonary haemodynamics and the clinical status of patients with pulmonary hypertension after 3 months of oral therapy.

Key Words: Pulmonary hypertension • Sildenafil


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Heart, March 1, 2008; 94(Suppl_1): i1 - i41.
[Full Text] [PDF]

Home page
 ThoraxHome page
National Pulmonary Hypertension Centres of the UK
Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland
Thorax, March 1, 2008; 63(Suppl_2): ii1 - ii41.
[Full Text] [PDF]

Home page
 CirculationHome page
G.-P. Diller and M. A. Gatzoulis
Pulmonary Vascular Disease in Adults With Congenital Heart Disease
Circulation, February 27, 2007; 115(8): 1039 - 1050.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
P. Fesler, A. Pagnamenta, B. Rondelet, F. Kerbaul, and R. Naeije
Effects of sildenafil on hypoxic pulmonary vascular function in dogs
J Appl Physiol, October 1, 2006; 101(4): 1085 - 1090.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
H. Baquero, A. Soliz, F. Neira, M. E. Venegas, and A. Sola
Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn: A Pilot Randomized Blinded Study
Pediatrics, April 1, 2006; 117(4): 1077 - 1083.
[Abstract] [Full Text] [PDF]

Home page
 Br J AnaesthHome page
E. B. Lobato, T. Beaver, J. Muehlschlegel, D. S. Kirby, C. Klodell, and A. Sidi
Treatment with phosphodiesterase inhibitors type III and V: milrinone and sildenafil is an effective combination during thromboxane-induced acute pulmonary hypertension
Br. J. Anaesth., March 1, 2006; 96(3): 317 - 322.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
E. Fung, R. R. Fiscus, A. P. C. Yim, G. D. Angelini, and A. A. Arifi
The Potential Use of Type-5 Phosphodiesterase Inhibitors in Coronary Artery Bypass Graft Surgery
Chest, October 1, 2005; 128(4): 3065 - 3073.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
A A Aldashev, B K Kojonazarov, T A Amatov, T M Sooronbaev, M M Mirrakhimov, N W Morrell, J Wharton, and M R Wilkins
Phosphodiesterase type 5 and high altitude pulmonary hypertension
Thorax, August 1, 2005; 60(8): 683 - 687.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. R. Wilkins, G. A. Paul, J. W. Strange, N. Tunariu, W. Gin-Sing, W. A. Banya, M. A. Westwood, A. Stefanidis, L. L. Ng, D. J. Pennell, et al.
Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) Study
Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1292 - 1297.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
A. J Lee, T. B Chiao, and M. P Tsang
Sildenafil for Pulmonary Hypertension
Ann. Pharmacother., May 1, 2005; 39(5): 869 - 884.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
B.K.S. Sastry and C. Narasimhan
Reply
J. Am. Coll. Cardiol., December 7, 2004; 44(11): 2256 - 2257.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.